EarlyCDT-Lung is a simple blood test ordered by a physician to aid in risk assessment and the early detection of lung cancer in high risk patients or patients with a CT nodule under surveillance. The test uses a panel of tumor antigens that are selected for their involvement in the development of lung cancer.
Autoantibodies form and circulate in the body at all stages of the disease including Stages I and II which are the earliest stages of lung cancer. Their measurement signifies the presence of cancerous cells.
The Oncimmune immuno-biomarker platform (EarlyCDT) provides increased sensitivity while maintaining higher levels of specificity than other single or multiple antigen tests. Elevation above a predetermined, cutoff value of any one immuno-biomarkers of the panel suggests that a tumor might be present.
Risk assessment and early detection of lung cancer in high-risk patient populations are the primary benefits of EarlyCDT-Lung. It is also used as a follow-up test for high-risk patients who have indeterminate lung nodules identified by CT. This means that when used in conjunction with diagnostic imaging, EarlyCDT-Lung has the potential to aid in the identification of lung cancer when treatment can be most successful, at a very early stage!
Watch a five-minute introductory video on EarlyCDT-Lung.